Group B Streptococcus, Perinatal
Clinical Snapshot
Group B Streptococcus (GBS, Streptococcus agalactiae) is a gram-positive bacterium that is a common, usually harmless component of the normal lower gastrointestinal and genital tract flora — an estimated 10-30% of pregnant people are colonized in the vagina and/or rectum at any given time, and colonization can be transient, intermittent, or persistent across a single pregnancy.[1] Colonization on its own is not an infection, causes no maternal symptoms in the great majority of cases, and does not by itself require antepartum treatment (see Non-Pharmacologic Management for why treating colonization before labour does not help).
The entire clinical stakes of this chapter are about the newborn. During labour and delivery — through ascending infection after membrane rupture or passage through a colonized birth canal — GBS can be vertically transmitted to the neonate. Roughly half of neonates born to a GBS-colonized parent become colonized themselves, and in the complete absence of intrapartum prophylaxis, about 1-2% of those exposed newborns go on to develop early-onset GBS disease: sepsis, meningitis, or pneumonia, historically one of the leading infectious causes of neonatal morbidity and mortality.[2] Universal antenatal screening paired with correctly timed intrapartum antibiotic prophylaxis (IAP) is the single most effective prevention strategy available and has transformed this disease's incidence — from roughly 1.8-4.0 cases per 1,000 live births before universal prevention strategies existed, down to approximately 0.2-0.25 cases per 1,000 live births in the contemporary screening-and-prophylaxis era.[1]
For a pharmacist, the highest-yield content here is the penicillin-allergy decision tree that determines which IAP agent is correct for a given patient (see Choose Initial Treatment) — a genuinely common, genuinely consequential decision point, since choosing the wrong agent can mean either an avoidable anaphylaxis risk or a prophylaxis regimen that silently fails against a resistant organism.
Recognize the Condition
Colonization, bacteriuria, and invasive disease are three different things
These three terms are often used loosely but describe genuinely different clinical situations, each with a different management implication.
The GBS spectrum in pregnancy
From harmless colonization to serious invasive disease.
Asymptomatic vaginal-rectal colonization
The common, expected finding on a routine 35-37 week screening culture. Not an infection, causes no maternal symptoms, and does not warrant antepartum antibiotic treatment — the only clinically effective intervention is correctly timed IAP at labour (see Choose Initial Treatment).
GBS bacteriuria
GBS identified on a routine prenatal urine culture, at any colony count, during the current pregnancy. This automatically classifies the patient as GBS-positive for intrapartum prophylaxis purposes, regardless of any later 35-37 week screening culture result (see Assessment & Diagnosis). A colony count of 10⁵ CFU/mL or higher meets the threshold for antepartum treatment as a urinary tract infection in its own right — but eradicating the bacteriuria antepartum does not remove the need for intrapartum GBS prophylaxis at labour.[1]
Invasive maternal GBS disease
Uncommon but clinically significant — chorioamnionitis, postpartum endometritis, or rarely bacteremia. Intrapartum chorioamnionitis needs broader-spectrum antibiotic coverage than GBS-specific IAP alone provides (see Red Flags & Refer and Treatment Failure/Next Step).
Early-onset neonatal GBS disease
Onset within the first 7 days of life, and in most cases within the first 24-48 hours — this is specifically what universal screening and IAP are designed to prevent. Presents as respiratory distress, grunting, apnea, temperature instability (fever or hypothermia), lethargy, poor feeding, hypotonia, and tachycardia or bradycardia, and can progress rapidly to septic shock, meningitis, or pneumonia.[2]
Late-onset neonatal GBS disease
Onset from 7 to 89 days of age, thought to reflect postnatal or environmental acquisition rather than intrapartum transmission. Intrapartum antibiotic prophylaxis does not prevent late-onset disease — an important expectation-setting point for patient counselling, since a normal, uneventful newborn period does not mean the GBS conversation is entirely closed.[1]
Risk Factors
Factors that indicate a need for intrapartum prophylaxis regardless of a negative or unavailable screening culture
- GBS bacteriuria at any colony count during the current pregnancy — automatically classified GBS-positive; no antenatal screening culture is needed to confirm this (see Assessment & Diagnosis).
- A previous infant affected by invasive GBS disease — automatically classified GBS-positive in this pregnancy regardless of any current culture result.
- Unknown GBS status at the onset of labour (no culture done, culture result unavailable, or culture collected more than 5 weeks before delivery — see Assessment & Diagnosis) together with any of the following:
- Preterm labour or delivery before 37 weeks' gestation.
- Rupture of membranes 18 hours or longer before delivery.
- Intrapartum fever ≥38°C (100.4°F).
Factors associated with GBS colonization or with early-onset disease
- Young maternal age.
- Multiparity is not protective — colonization status can differ between pregnancies in the same person, which is why every pregnancy is screened independently rather than relying on a previous pregnancy's result (short of the two automatic-positive exceptions above).
- Multiple gestation — same screening and management principles apply, with no unique dosing change for GBS prophylaxis itself (see Special Populations).
- Population-level epidemiologic data show higher early-onset GBS disease rates among Black infants in North America compared with other groups, for reasons not fully explained by identified risk-factor differences alone — a disparity worth being aware of rather than a reason to alter individual screening or prophylaxis practice, which remains universal.[1]
Red Flags & Refer
Escalate for immediate evaluation — neonatal or obstetric, as specified — for any of the following:
- Any sign of early-onset neonatal sepsis — respiratory distress, grunting, apnea, temperature instability (fever or hypothermia), lethargy, poor feeding, hypotonia, or tachycardia/bradycardia — in a newborn at any point, but especially within the first 24-48 hours of life. This needs immediate neonatal evaluation regardless of maternal GBS status or IAP history (see Monitoring & Follow-Up for the full evaluation pathway).[4]
- Maternal signs of chorioamnionitis during labour — fever ≥38°C together with any of maternal tachycardia, fetal tachycardia, uterine tenderness, foul-smelling amniotic fluid, or maternal leukocytosis. This requires broader-spectrum antibiotic treatment beyond GBS-specific prophylaxis (typically ampicillin plus gentamicin, with additional anaerobic coverage considered at delivery per institutional protocol) — a GBS-only regimen is not adequate treatment for suspected chorioamnionitis.[2]
- A reported penicillin allergy with features suggesting a high-risk (anaphylaxis-type) reaction — this needs to be identified and routed to the correct IAP regimen (see Choose Initial Treatment) before the patient is in active labour, not discovered for the first time at the bedside.
- Postpartum signs of endometritis — fever, uterine tenderness, foul-smelling lochia — particularly after prolonged labour or prolonged rupture of membranes.
Assessment & Diagnosis
Universal antenatal screening
Offer every pregnant patient a combined vaginal-rectal swab culture for GBS — one swab passed first through the lower vagina, then through the anal sphincter into the rectum — regardless of planned mode of delivery, including patients planning a cesarean birth (since labour can begin, or membranes can rupture, before a scheduled cesarean occurs).[3]
Timing: SOGC recommends screening at 35-37 weeks' gestation.[3] ACOG's more recently updated window is 36 0/7 to 37 6/7 weeks — a small shift specifically designed to extend the culture's validity window to cover births up to 41 0/7 weeks (see below), since the original 35-week starting point left a shorter margin for a patient who delivers at or near term.[2] Follow local hospital protocol for the exact window used; the key point for pharmacist counselling is that this is a universal, culture-based screening approach, not one restricted to patients with identifiable risk factors — universal screening has been shown to be more sensitive than a risk-factor-based approach at identifying patients who will benefit from IAP.[1]
Culture validity window: a negative screening culture is considered valid for 5 weeks from collection. A patient who delivers more than 5 weeks after her screening culture is managed as though her GBS status is unknown at labour — this is the practical reason ACOG shifted the recommended screening window later, to keep more patients' cultures valid through a wider range of delivery timing.[2]
Who does not need a screening culture — automatic GBS-positive classification
Two groups are classified as GBS-positive by history alone, and a 35-37 week screening culture is not needed (and cannot override this classification even if it comes back negative):
- GBS bacteriuria identified at any colony count during the current pregnancy (from a routine prenatal urine culture, regardless of whether it met the ≥10⁵ CFU/mL threshold for antepartum UTI treatment).
- A previous infant affected by invasive GBS disease, in any prior pregnancy.
Susceptibility testing — plan ahead for the penicillin-allergy pathway
For any patient reporting a high-risk penicillin allergy (see Choose Initial Treatment for the risk-stratification criteria), order clindamycin (and erythromycin) susceptibility testing on the GBS isolate at the time the screening culture is collected — including reflex testing for inducible clindamycin resistance (D-zone testing) if the isolate is erythromycin-resistant. Ordering this proactively, rather than waiting until the patient presents in labour, is what makes the clindamycin option actually usable when it is needed (see Choose Initial Treatment).[1]
Intrapartum status unknown
A patient presenting in labour with genuinely unknown GBS status (no culture performed, result unavailable, or culture more than 5 weeks old) is managed using the risk-factor criteria in Risk Factors — treat as GBS-positive if preterm labour/delivery, rupture of membranes ≥18 hours, or intrapartum fever ≥38°C is present. A rapid intrapartum nucleic acid amplification test (NAAT), where available, can inform this decision in real time for a patient with unknown status and no risk factor, but is not required and does not replace universal antenatal culture-based screening as the primary strategy.[2]
Treatment Targets
- Correctly identify GBS-positive status through universal antenatal screening, or through the recognized automatic-positive exceptions (GBS bacteriuria this pregnancy, previous affected infant).
- Prevent early-onset neonatal GBS sepsis, meningitis, and pneumonia through correctly selected, correctly timed intrapartum antibiotic prophylaxis.
- Select the correct IAP agent for every patient, navigating the penicillin-allergy decision tree accurately — avoiding both an avoidable anaphylaxis risk from a first-line beta-lactam and an unnecessarily broad-spectrum agent (clindamycin without confirmed susceptibility, or vancomycin) when a narrower option is genuinely safe.
- Achieve adequate antibiotic exposure (≥4 hours before delivery) whenever feasible, without inappropriately delaying an otherwise medically indicated delivery to "complete" that window.
- Recognize and treat intrapartum chorioamnionitis with appropriately broad-spectrum antibiotics, distinct from GBS-specific prophylaxis.
- Ensure appropriate postnatal observation of the newborn, matched to maternal risk factors and the adequacy of intrapartum prophylaxis actually received.
- Avoid antepartum antibiotic treatment of asymptomatic GBS colonization outside of labour, which does not reduce neonatal risk and unnecessarily promotes antimicrobial resistance.
Choose Initial Treatment
IAP is indicated for any of the following, once labour begins or membranes rupture: a positive 35-37 week (or 36 0/7-37 6/7 week) screening culture; GBS bacteriuria at any colony count this pregnancy; a previous infant with invasive GBS disease; or unknown GBS status together with a risk factor (preterm labour/delivery, rupture of membranes ≥18 hours, or intrapartum fever ≥38°C).[3][1]
Not indicated for a GBS-positive patient undergoing a genuinely pre-labour, intact-membrane planned cesarean delivery — with no labour and no rupture of membranes, transmission risk is negligible and IAP is not recommended in this specific scenario. If labour begins or membranes rupture before the scheduled cesarean, standard IAP indications then apply.[3]
Preferred penicillin G 5 million units IV initial (loading) dose, then 2.5-3.0 million units IV every 4 hours until delivery. Preferred over ampicillin for its narrower spectrum.[1]
Acceptable alternative ampicillin 2 g IV initial dose, then 1 g IV every 4 hours until delivery.[1]
This is the highest-stakes decision point in this chapter. Classify every reported penicillin allergy as low-risk or high-risk before selecting an agent:
Low-risk allergy a distant, vague, or reported-only history, or a reaction limited to an isolated maculopapular rash without any systemic or immediate hypersensitivity feature.
High-risk allergy a history of anaphylaxis, angioedema, respiratory distress, or urticaria occurring immediately after exposure to a penicillin — or to a cephalosporin, which raises the same concern given shared structural features.[2]
Preferred cefazolin 2 g IV initial dose, then 1 g IV every 8 hours until delivery. Cross-reactivity between penicillins and cefazolin is low, and cefazolin has more reliable activity against GBS than clindamycin or vancomycin — the reason it is preferred over those agents whenever the allergy itself is low-risk.[1]
Preferred, only if susceptibility confirmed clindamycin 900 mg IV every 8 hours until delivery — use only if the GBS isolate has been confirmed susceptible to clindamycin (and, if erythromycin-resistant, negative for inducible clindamycin resistance on D-zone testing) on antenatal culture susceptibility testing (see Assessment & Diagnosis, where this testing is ordered proactively for exactly this reason).[1]
Susceptibility resistant, unknown, or unavailable vancomycin 20 mg/kg IV every 8 hours (maximum 2 g per dose) until delivery. Vancomycin is the only agent with validated pharmacokinetic and microbiologic adequacy for this indication when clindamycin susceptibility cannot be confirmed — do not use clindamycin empirically in a high-risk-allergy patient without a confirmed susceptibility result; clindamycin resistance among GBS isolates is common enough that empiric use risks a silent prophylaxis failure.[1]
IAP is considered adequate when penicillin G, ampicillin, or cefazolin is administered 4 or more hours before delivery — this interval is needed to achieve sufficient fetal/neonatal antibiotic levels. Clindamycin and vancomycin do not have an equivalent validated "adequate" timing threshold and are treated as inherently less certain regardless of duration.[4]
Do not delay an otherwise medically indicated delivery solely to complete the 4-hour window — start IAP as soon as the decision is made, even if less than 4 hours will elapse before delivery, and flag the resulting inadequate prophylaxis to the neonatal team so appropriate newborn observation can be planned (see Monitoring & Follow-Up).[2]
If intrapartum chorioamnionitis is suspected (see Red Flags & Refer), start broader-spectrum treatment (typically ampicillin plus gentamicin, with additional anaerobic coverage considered at delivery per institutional protocol) rather than relying on the GBS-specific regimen above, which is not adequate treatment for this distinct diagnosis.[2]
Non-Pharmacologic Treatment
- There is no effective non-pharmacologic strategy for preventing GBS transmission to the newborn — correctly timed IAP at labour is the only intervention shown to reduce early-onset disease risk.
- Intravaginal chlorhexidine washing during labour has been studied specifically as a possible alternative or adjunct to IAP and has not been shown to reduce the incidence of neonatal GBS disease — it is not recommended as a substitute for antibiotic prophylaxis.[1]
- Oral or vaginal probiotics to reduce antenatal GBS colonization have insufficient evidence of efficacy and are not recommended as a substitute for IAP.
- Antepartum antibiotic treatment of an asymptomatic positive screening culture, before labour, is not recommended — recolonization after antepartum treatment is common, so treating the culture result itself (rather than treating at labour) does not reliably reduce neonatal transmission risk and unnecessarily contributes to antimicrobial resistance pressure.
- Mode of delivery should not be altered because of GBS-positive status alone — a cesarean delivery is not offered, and does not need to be offered, purely to avoid GBS transmission; IAP indications and exceptions are as described in Choose Initial Treatment regardless of the planned delivery route.
- Standard newborn care — delayed cord clamping, skin-to-skin contact, and routine feeding support — is not altered by maternal GBS status alone in a well-appearing infant with adequate maternal IAP.
- Patient counselling at the time of screening (ideally well before labour) should explain that a positive result means colonization, not an infection needing treatment right now, and should set expectations for what happens at hospital admission (an IV antibiotic started once labour begins or membranes rupture) — this avoids confusion or alarm when the plan is explained again at triage.
Special Populations
Preterm labour and PPROM with unknown GBS status
A patient presenting in threatened or actual preterm labour, or with preterm premature rupture of membranes (PPROM), whose GBS status is unknown should have a screening culture collected at admission and be started on IAP empirically while that result (or the clinical course) is pending — preterm delivery is itself one of the risk-factor criteria that triggers empiric treatment for unknown status (see Risk Factors). IAP for GBS is a distinct consideration from the broader-spectrum latency antibiotics sometimes used to prolong pregnancy after PPROM; both may be indicated concurrently per institutional protocol.[3]
Planned cesarean delivery
As noted in Choose Initial Treatment, IAP is not indicated for a GBS-positive patient undergoing a genuinely pre-labour, intact-membrane planned cesarean — but universal screening is still offered to this group, since labour or rupture of membranes can occur before the scheduled procedure and would then trigger standard IAP indications.[3]
Multiple gestation
The same screening timing, IAP indications, and dosing apply — there is no unique dose adjustment for GBS prophylaxis specifically in a twin or higher-order pregnancy.
Renal impairment
Vancomycin dosing may need adjustment for significant renal impairment; consult institutional protocol or pharmacy for weight- and renal-function-based dosing in this situation rather than using the standard interval unmodified.
Obesity
Some institutional protocols use a higher vancomycin loading approach in patients with a significantly elevated body mass index; follow local protocol.
Breastfeeding
Penicillin G, ampicillin, cefazolin, clindamycin, and vancomycin are all considered compatible with breastfeeding.
Neonatal implications of inadequately prophylaxed exposure
Infants born to a GBS-positive (or risk-factor-treated) parent who did not receive adequate IAP — defined as penicillin G, ampicillin, or cefazolin given 4 or more hours before delivery — require closer clinical observation after birth per current well-baby protocols, even when the infant appears entirely well at delivery (see Monitoring & Follow-Up for the specific observation pathway). This is a genuinely common real-world scenario — labour that progresses faster than the 4-hour window allows — and does not by itself mean something went wrong; it means the newborn care plan needs to reflect it.[4]
Monitoring & Follow-Up
Neonatal observation, stratified by maternal IAP adequacy and infant appearance
Current guidance moves away from automatic blood work and empiric antibiotics for every GBS-exposed newborn, toward a more individualized approach based on the infant's clinical appearance and the adequacy of maternal prophylaxis actually received.[4]
- Ill-appearing infant, at any point: full diagnostic evaluation (blood culture, CBC with differential, and consideration of lumbar puncture and chest x-ray if respiratory symptoms are present) and immediate empiric antibiotic therapy, regardless of maternal GBS status or IAP history.
- Well-appearing infant, but the mother had signs of chorioamnionitis: blood culture ± CBC with differential, with empiric antibiotics started pending results.
- Well-appearing infant, no maternal chorioamnionitis, IAP adequate (penicillin G, ampicillin, or cefazolin ≥4 hours before delivery): routine newborn care and standard observation — no additional GBS-specific testing or intervention is required.
- Well-appearing infant, no maternal chorioamnionitis, IAP inadequate or not given despite an indication: serial vital signs and clinical examinations for 36-48 hours before discharge, rather than automatic blood culture and empiric antibiotics for every such infant. Some institutions instead use a validated multivariate neonatal early-onset sepsis risk calculator to individualize this decision — follow local protocol for which approach is in use.[4]
Maternal postpartum monitoring
Watch for signs of postpartum endometritis (fever, uterine tenderness, foul-smelling lochia), particularly after prolonged labour or prolonged rupture of membranes.
Handoff to the neonatal/pediatric team
Clearly document and communicate maternal GBS status, the specific IAP agent given, the time it was started relative to delivery, and whether the 4-hour adequacy threshold was met — this information directly drives the neonatal observation pathway above, and an incomplete handoff is a genuine, avoidable patient-safety gap.
Common Errors to Avoid
- Treating a positive antenatal screening culture with oral antibiotics before labour, in the belief this "clears" the GBS — recolonization is common, and this does not reliably reduce neonatal transmission risk; the only effective intervention is correctly timed IAP at labour.
- Withholding IAP from a GBS-positive patient undergoing induced labour, under the mistaken belief that only spontaneous labour requires prophylaxis — any labour or rupture of membranes in a GBS-positive patient needs IAP, whether induced or spontaneous.
- Giving IAP to a GBS-positive patient undergoing a genuinely pre-labour, intact-membrane planned cesarean delivery — not indicated in this specific scenario, and unnecessarily exposes the patient to antibiotics.
- Classifying a mild, remote, or vague reaction as a "penicillin allergy" requiring cefazolin, clindamycin, or vancomycin without taking a real allergy history — over-classifying low-risk reactions as high-risk pushes patients toward broader-spectrum agents unnecessarily.
- Using clindamycin empirically for a high-risk penicillin allergy without a confirmed susceptibility result — resistance is common enough that this risks a silent prophylaxis failure.
- Treating GBS bacteriuria found on a routine prenatal urine culture as fully resolved with the standard antepartum UTI antibiotic course, and forgetting that this same patient still needs intrapartum GBS prophylaxis at labour regardless of whether the bacteriuria was successfully eradicated.
- Ordering (or requiring) a 35-37 week screening culture in a patient who already has a previous infant with invasive GBS disease — she is already GBS-positive by definition, and a culture (even a negative one) cannot override that classification.
- Treating a negative screening culture as permanently reassuring — cultures are valid for only 5 weeks, and a patient who develops a genuinely new risk factor (preterm labour, prolonged rupture of membranes, intrapartum fever) after a negative or expired culture still needs individualized reassessment.
- Failing to clearly document and hand off maternal GBS status and IAP adequacy to the neonatal/pediatric team — this information directly drives the newborn observation plan.
- Implying to patients that IAP protects against GBS disease broadly — it specifically prevents early-onset disease; it does not prevent late-onset disease occurring after the first week of life.
Clinical Decision Algorithm
Drug Tables
How to use this table: doses are adult intrapartum obstetric doses for GBS prophylaxis specifically and require patient-specific confirmation (renal function, weight, true allergy history). Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
First-Line Prophylaxis — No Penicillin Allergy
Penicillin G is preferred given its narrow spectrum; ampicillin is an acceptable alternative.[1]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Penicillin G | 5 million units IV initial dose, then 2.5-3.0 million units IV every 4 hours until delivery | Hypersensitivity reactions, rarely anaphylaxis | None significant for this short-course intrapartum use | 1st-line agent — confirm allergy history before administering. Adequate prophylaxis requires ≥4 hours before delivery. |
| Ampicillin | 2 g IV initial dose, then 1 g IV every 4 hours until delivery | Hypersensitivity reactions, GI upset | None significant for this short-course intrapartum use | Acceptable alternative to penicillin G — broader spectrum, so penicillin G remains preferred when there is no reason to choose ampicillin specifically. |
Penicillin-Allergic — Low-Risk Allergy
An isolated maculopapular rash, or a distant/vague history without an immediate hypersensitivity feature, is classified low-risk.[2]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Cefazolin | 2 g IV initial dose, then 1 g IV every 8 hours until delivery | Hypersensitivity reactions (low cross-reactivity risk with penicillin) | None significant for this short-course intrapartum use | Preferred over clindamycin or vancomycin in low-risk allergy — more reliable GBS activity than either of those agents. |
Penicillin-Allergic — High-Risk Allergy (Anaphylaxis, Angioedema, Respiratory Distress, or Immediate Urticaria)
Agent selection depends entirely on antenatal clindamycin susceptibility testing (see Assessment & Diagnosis, where this is ordered proactively).[1]
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Clindamycin | 900 mg IV every 8 hours until delivery | GI upset, rare C. difficile-associated diarrhea | None significant for this short-course intrapartum use | Use only with a confirmed clindamycin-susceptible GBS isolate (and, if erythromycin-resistant, a negative inducible-resistance/D-zone test). Never use empirically in a high-risk-allergy patient. |
| Vancomycin | 20 mg/kg IV every 8 hours, maximum 2 g per dose, until delivery | Infusion-related flushing reaction, nephrotoxicity, ototoxicity (rare with short-course intrapartum use) | Additive nephrotoxicity with other nephrotoxic agents | Used when clindamycin susceptibility is resistant, unknown, or unavailable — the only agent with validated pharmacokinetic/microbiologic adequacy in this setting. Infuse over 60+ minutes to reduce infusion-reaction risk; adjust for renal impairment per institutional protocol. |
A different diagnosis, not GBS-specific prophylaxis
| Regimen | Dosage | Indication | Drug interactions | Comments |
|---|---|---|---|---|
| Ampicillin + gentamicin | Per institutional chorioamnionitis protocol | Suspected intrapartum chorioamnionitis, not routine GBS prophylaxis | Additive nephrotoxicity/ototoxicity between aminoglycosides and other nephrotoxic or ototoxic agents | A GBS-specific regimen above is not adequate treatment for suspected chorioamnionitis — see Red Flags & Refer and Treatment Failure/Next Step. |
Evidence note: drug inventory, dosing, and comments reflect the current SOGC guideline, cross-checked against the CDC and ACOG guidance it draws from for exact dosing intervals.[3][1][2]
References
- Prevention of Perinatal Group B Streptococcal Disease: Revised Guidelines from CDC, 2010 — MMWR Recommendations and Reports, Centers for Disease Control and Prevention (Verani JR, McGee L, Schrag SJ). MMWR Recomm Rep 2010;59(RR-10):1-36
- Committee Opinion No. 797: Prevention of Group B Streptococcal Early-Onset Disease in Newborns — Obstetrics & Gynecology, American College of Obstetricians and Gynecologists (Committee on Obstetric Practice). Obstet Gynecol 2020;135(2):e51-e72
- No. 298-The Prevention of Early-Onset Neonatal Group B Streptococcal Disease — Journal of Obstetrics and Gynaecology Canada, Society of Obstetricians and Gynaecologists of Canada (Money D, Allen VM). J Obstet Gynaecol Can 2013;35(10):939-948 (Reaffirmed 2018)
- Management of Infants at Risk for Group B Streptococcal Disease — Pediatrics, American Academy of Pediatrics, Committee on Fetus and Newborn and Committee on Infectious Diseases (Puopolo KM, Lynfield R, Cummings JJ). Pediatrics 2019;144(2):e20191881
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.